Genetic Technologies (AU:GTG) has released an update.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks straight to you inbox with TipRanks' Smart Value Newsletter
Rhythm Biosciences Ltd has acquired the Genetype genetic risk assessment business, enhancing its oncology portfolio with an immediate revenue stream and growth potential. This strategic acquisition allows Rhythm to leverage Genetype’s expertise and expand its market presence in both Australia and the US. The integration of Genetype’s technology and team is expected to drive accelerated commercial growth and diversification.
For further insights into AU:GTG stock, check out TipRanks’ Stock Analysis page.
Trending Articles:
Looking for a trading platform? Check out TipRanks' Best Online Brokers , and find the ideal broker for your trades.
Report an Issue